Portfolio company Artios Pharma, which is focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), has announced the appointment of Dr Simon Boulton as Vice President (VP) Science Strategy.
In his new role, Simon will play an important role in assisting the business development team in the identification and evaluation of new pipeline opportunities from the global academic and industrial DDR network. Simon will also provide scientific leadership and support to the ongoing development of the two lead DDR programmes that Artios has in-licensed from Cancer Research Technology (CRT), the development and commercialisation arm of CRUK, one of which originated from Simon’s research group while based at Clare Hall laboratory. This will play to his strengths as a world-leading researcher in the field of DNA repair and the treatment of cancer resulting from DNA damage.
Simon will join the newly formed leadership team at Artios Pharma, alongside his current and principal position as Senior Group Leader at the newly formed Francis Crick Institute, London. This management team combines a strong track record of product discovery and development in the DDR field together with considerable transactional and operational experience in rapidly growing companies.
Dr Niall Martin, Chief Executive Officer of Artios Pharma, said:
“Following our recent successful £25 million fundraise and subsequent launch of Artios as a new company focussed on developing new DDR targeted cancer therapies, we are delighted to welcome Dr Simon Boulton to our management team. Simon brings with him considerable DDR experience and a wealth of contacts and knowledge in the field, all of which will be invaluable as we continue to build a pipeline of first-in-class DDR programmes and establish Artios as a leading player in the DDR field.”